In the phase 3 study (NCT03370913), a single infusion of valoctocogene roxaparvovec at 6 × 1013 vg/kg was administered to 134 adult males with severe hemophilia A (FVIII ≤ 1 IU/dL) without inhibitors [36]. The gene discussed is F8; the disease is hemophilia A.